The category is growing fast off a genuinely small base, and that gap between market size and capital allocation is the opportunity itself.
Women's health funding keeps setting new highs, yet the category remains structurally undercapitalised relative to the market it actually serves, which is the tension every founder in the space is currently pitching against.
A record that's still a rounding error
Women's health investment hit a record $2.6B in 2024, a 55% increase over 2023, according to a Silicon Valley Bank report.
Despite that jump, the World Economic Forum's 2026 outlook notes the category has historically captured only about 6% of private healthcare investment, even though women represent roughly half the population. The global women's health market is valued at $430-440B today and is projected to exceed $600B by 2030.
Put those numbers together and 2024's record raise represents roughly 0.6% of the market's current annual value, a sign of just how early this capitalisation cycle still is relative to the size of the opportunity. One investor framed the broader stakes even higher, estimating women's health improvements could add roughly $1 trillion to the global economy annually by 2040, with an estimated $3 in economic growth for every $1 invested.
The re-rating setup investors look for
A large, growing addressable market paired with historically thin capital allocation is exactly the setup investors look for when a category is about to re-rate.
One investor summed up the opportunity plainly: "the health of women is massive, proven, and fundable," reframing the category as unmet financial upside rather than a niche cause.
It also explains why a widening set of specialist funds, some deploying $500K to $2M checks, others running full funds north of $70M, are now deploying capital specifically into women's health, rather than treating it as a line item inside a broader healthcare fund. That's a structural shift in who's actually writing the checks, not just how many checks are being written.
The sub-categories catching up
Watch whether full-year 2026 figures beat 2024's record once they are reported, and track which sub-categories, menopause, oncology diagnostics and hormonal conditions among them, grow fastest off their current low base.
Also watch whether the broadest, most active investors, the ones with 100-plus portfolio companies across cardiovascular, bone, autoimmune and oncology alongside fertility and menopause, keep expanding their women's health allocation or start concentrating it, since that's where the next wave of specialist funds is likely to take its cue.
